Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States.

ABSTRACT:

Introduction

The choice of BCR-ABL1 tyrosine kinase inhibitors (TKI) for the first line of therapy (LOT) for chronic-phase chronic myeloid leukemia (CML) is tailored to disease risk and patient characteristics like comorbidities, which become more prevalent with age. However, contemporary evaluations of frontline TKI choice and the factors associated with TKI switching in this specific patient population are lacking.

Methods

We sought to describe TKI use in older patients (age: 66-99 years) with CML in the United States. Using the Surveillance, Epidemiology, and End Results-Medicare-linked database, we identified 810 older (median age: 75 years, interquartile range: 70-80 years) patients diagnosed during 2007-2015.

Results

Imatinib was the most common frontline TKI (6

SUBMITTER: Shallis RM 

PROVIDER: S-EPMC8832334 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature